Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy

Hepato-Gastroenterology

Volumn 56, Issue 91-92, 2009, Pages 703-706

  Saitoh, Toshihito ^a   Otsuka, Hiroko ^a   Kawasaki, Takahiro ^a   Endo, Hitoshi ^a   Iga, Daijirou ^a   Tomimatsu, Masahiko ^a   Fukushima, Yasushi ^b   Katsube, Takao ^a   Ogawa, Kenji ^a   Otsuka, Kuniaki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

CYP2C19; Helicobacter pylori; Maintenance acid suppression; PPI; Recurrence of GERD

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HOMOZYGOSITY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENT DISEASE; REFLUX ESOPHAGITIS; TREATMENT DURATION;

ADULT; AGE FACTORS; AGED; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; ESOPHAGITIS, PEPTIC; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMANS; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; RECURRENCE; SEX FACTORS; TREATMENT OUTCOME;

EID: 67651203013     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Yamagishi H, Koike T, Ohara S, Kobayashi S, Ariizumi K, Abe Y, Iijima K, Imatani A, Inomata Y, Kato K, Shibuya D, Aida S, Shimosegawa T: Prevalence of gastroesophageal reflux symptoms in a large unselected general population in Japan. World J Gastroenterol 2008; 14:1358-1364.
2. Nocon M, Labenz J, Jaspersen D, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN: Long- term treatment of patients with gastro- oesophageal reflux disease in routine care - results from the ProGERD study. Aliment Pharmacol Ther 2007; 25:715-722. (Pubitemid 46272517)
3. Edwards SJ, Lind T, Lundell L: Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001; 5:1729-1736. (Pubitemid 33001136)
4. Ishizaki T, Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L: Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994; 16:214-215. (Pubitemid 24096631)
5. Horn J: Review article: relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole. Aliment Pharmacol Ther 2004; 20(Suppl 6):11-19. (Pubitemid 39593283)
6. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T: Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5:161-202.
7. Yamano H, Matsushita H, Yanagiwara S: Administration of rabeprazole for 8 weeks in gastro-oesophageal reflux disease patients, its plasma concentration, the intragastric pH elevation and the healing efficacy. J Gastroenterol Hepatol 2008; 23:534-540.
8. Ariizumi K, Ohara S, Koike T, Inomata Y, Iijima K, Sekine H, Noguchi M, Sugiyama K, Eda Y, Kayaba S, Kawamura M, Shimosegawa T: Therapeutic effects of 10mg/day rabeprazole administration on reflux oesophagitis was not influenced by the CYP2C19 polymorphism. J Gastroenterol Hepatol 2006; 21:1428-1434. (Pubitemid 44154712)
9. Furuta T, Shirai N, Watanabe F, Honda S, Takeuchi K, Iida T, Sato Y, Kajimura M, Futami H, Takayanagi S, Yamada M, Ohashi K, Ishizaki T, Hanai H: Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72:453-456. (Pubitemid 35178870)
10. Thjodleifsson B: Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002; 19:911-927. (Pubitemid 36092253)
11. Pilotto A, Franceschi M, Leandro G, Scarcelli C, D'Ambrosio LP, Paris F, Annese V, Seripa D, Andriulli A, Di Mario F: Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J Gastroenterol 2007; 13:4467-4472. (Pubitemid 47412409)
12. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)- mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46:594-598. (Pubitemid 24334747)
13. Carlsson R, Dent J, Bolling-Sternevald E, Johnsson F, Junghard O, Lauritsen K, Riley S, Lundell L: The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33:1023-1029. (Pubitemid 28505643)
14. Dent J, Yeomans ND, Mackinnon M, Reed W, Narielvala FM, Hetzel DJ, Solcia E, Shearman DJ: Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35:590-598. (Pubitemid 24163780)
15. Devault KR, Johanson JF, Johnson DA, Liu S, Sostek MB: Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol 2006; 4:852-859.
16. Lauritsen K, Devière J, Bigard MA, Bayerdörffer E, Mózsik G, Murray F, Kristjansdóttir S, Savarino V, Vetvik K, De Freitas D, Orive V, Rodrigo L, Fried M, Morris J, Schneider H, Eklund S, Larkö A: Esomeprazole 20mg and lansoprazole 15mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17(Suppl 1):24;discussion 25-27. (Pubitemid 36255911)
17. Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH: Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996; 10:529-539. (Pubitemid 26254796)
18. Robinson M, Lanza F, Avner D, Haber M: Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124:859-867.
19. Thjodleifsson B, Rindi G, Fiocca R, Humphries TJ, Morocutti A, Miller N, Bardhan KD; European Rabeprazole Study Group: A randomized, double-blind trial of the efficacy and safety of 10 or 20mg rabeprazole compared with 20mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 2003; 17:343-351. (Pubitemid 36259396)
20. Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ: Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci 2000; 45:845-853. (Pubitemid 30238242)
21. Birbara C, Breiter J, Perdomo C, Hahne W: Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. Eur J Gastroenterol Hepatol 2000; 12:889-897. (Pubitemid 30663901)
22. McColl KE, Kennerley P: Proton pump inhibitors-differences emerge in hepatic metabolism. Dig Liver Dis 2002; 34:461-467. (Pubitemid 34830685)
23. Kawamura M, Ohara S, Koike T, Iijima K, Suzuki H, Kayaba S, Noguchi K, Abe S, Noguchi M, Shimosegawa T: Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. J Gastroenterol Hepatol 2007; 22:222-226. (Pubitemid 46181352)
24. Kawamura M, Ohara S, Koike T, Iijima K, Suzuki J, Kayaba S, Noguchi K, Hamada S, Noguchi M, Shimosegawa T; Study Group of GERD: The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther. 2003; 17:965-973.
25. el-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE: Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109:681-691.
26. Haruma K, Kamada T, Kawaguchi H, Okamoto S, Yoshihara M, Sumii K, Inoue M, Kishimoto S, Kajiyama G, Miyoshi A: Effect of age and Helicobacter pylori infection on gastric acid secretion. J Gastroenterol Hepatol 2000; 15:277-283.